Triclofos

CHEMBL1201317 Phase 4 Одобрено Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
229.4 g/mol
LogP
0.3
Phase
4

Triclofos is a prodrug of trichloroethanol (similar to chloral hydrate) that is metabolized in the body to the active CNS depressant trichloroethanol, which potentiates GABA-A receptor activity to produce sedation, hypnosis, and anxiolysis. It is used as a sedative for procedural sedation in children and for insomnia, particularly as a pre-medication before EEG recordings or imaging procedures requiring pediatric sedation. Its slower onset compared to chloral hydrate and less pungent taste make it somewhat more acceptable in pediatric use.

Молекулярная масса

229,3800 g/mol

LogP

0,30

TPSA

66,80 Ų

Правило пяти Липинского

Соответствует

Механизм действия

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Механизм

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

2D Структура

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

O=P(O)(O)OCC(Cl)(Cl)Cl

InChI

InChI=1S/C2H4Cl3O4P/c3-2(4,5)1-9-10(6,7)8/h1H2,(H2,6,7,8)

Molecular Formula

C2H4Cl3O4P

HBD / HBA

2 / 4

Вращаемые Связи

2

Тяжёлые Атомы

10

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Часто задаваемые вопросы

Triclofos is a prodrug of trichloroethanol (similar to chloral hydrate) that is metabolized in the body to the active CNS depressant trichloroethanol, which potentiates GABA-A receptor activity to produce sedation, hypnosis, and anxiolysis. It is used as a sedative for procedural sedation in children and for insomnia, particularly as a pre-medication before EEG recordings or imaging procedures requiring pediatric sedation. Its slower onset compared to chloral hydrate and less pungent taste make it somewhat more acceptable in pediatric use.

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

Yes, Triclofos is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201317. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 5563. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Медицинский отказ от ответственности

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.